Meta-analysis · people
Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulin
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
For people with type 2 diabetes already on insulin and near their goal, adding pramlintide was linked to a further small HbA1c drop and some weight loss, without more severe low blood sugar events.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2003
- Journal
- Diabetes Obes Metab
What they tested
The team asked whether adding pramlintide to insulin lowers HbA1c and weight in people with type 2 diabetes who are close to, but not yet at, their blood sugar goals.
How the study was done
A pooled post hoc analysis of two randomized, double-blind, placebo-controlled trials, limited to insulin users with type 2 diabetes whose starting HbA1c (a long-term average of blood sugar) was between 7.0 and 8.5%. In this group, 80 people got placebo (a dummy shot) plus insulin and 86 got pramlintide at 120 micro g twice daily plus insulin, followed for 26 weeks.

Model. Individual results vary.
What they found
Both groups started with an average HbA1c of 8.0%. At week 26, the pramlintide arm's HbA1c was 0.43% lower and its weight 2.0 kg lower than the placebo arm's, and both differences were statistically significant (p < 0.001). Severe low blood sugar events did not rise with pramlintide: 0.13 events per patient year versus 0.19 with placebo.
What it doesn’t show
This was a post hoc look at a subset of patients from two earlier trials, chosen after the trials were done rather than planned in advance. It lasted 26 weeks and covered only people with type 2 diabetes already on insulin.
The paper
Hollander et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003.
The compound
More studies on Pramlintide
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose groupRandomized trial · people · 2023
- Pramlintide: weight loss maintained over 12 months in obesityRandomized trial · people · 2008
- Pramlintide: 3.7% placebo-corrected weight loss at 16 weeksRandomized trial · people · 2007
- Pramlintide lowered post-meal glucagon and glucose in type 2 diabetesRandomized trial · people · 2002
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.